Published in Cancer Weekly, July 18th, 2006
"Tumors are angiogenesis dependent. Preclinical studies have shown that well-tolerated continuous low dose, i.e. metronomic, chemotherapy can exert significant antiangiogenic effects and thereby a greater antitumor influence than conventional chemotherapy with high, spaced-out bolus doses," scientists writing in the journal Acta Oncologica report.
"There are however, no means of quantitatively assessing the antiangiogenic effect per se of chemotherapy in tumors. We therefore used...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.